Compare Merck & Co., Inc. (MRK) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Micron Technology, Inc. — how do they compare? Merck & Co., Inc. trades at $126.24 (market cap $307.25B), while Micron Technology, Inc. trades at $977.13 (market cap $977.44B). The key difference: Micron Technology, Inc. is far larger — about 3.2× Merck & Co., Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| MRK | MU | |
|---|---|---|
Market Cap | $307.25B | $977.44B |
Sector | Health | Technology |
52-Week High | $129.52 | $1.21K |
52-Week Low | $77.60 | $104.88 |
Enterprise Value | $350.66B | $957.80B |
Dividend Yield | 2.73% | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Micron Technology (MU) surged 14.36% to $970.82, driven by strong AI memory demand and positive analyst sentiment. The stock shows robust fundamentals with a P/E of 19.56 and net income margin of 55.91%, supported by three consecutive quarterly earnings beats. Technical indicators are mixed, with a bearish moving average signal but oversold RSI levels suggesting potential rebound. Recent news highlights AI-driven memory chip demand and strategic customer agreements fueling growth optimism.
Outlook remains bullish due to AI super-cycle tailwinds and projected 2026 revenue of $90.3B, though risks include cyclical semiconductor demand and high valuation multiples. Analyst consensus strongly favors Buy with a $1,550 price target, indicating ~60% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
